Evidence map›Paper›PMID 36976664›Full record

ReviewNeurology international2023

Transcranial Stimulation for the Treatment of Stimulant Use Disorder.

Amber N Edinoff, Saveen Sall, T Dean Roberts, Henry H Tomlinson, Lenise G Soileau, Eric D Jackson, Kevin S Murnane, Danielle M Wenger, Elyse M Cornett, Jaime Toms and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Neurology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Novel neurotherapeutic targets for substance use disorders: Neuroplasticity, neuroinflammation, gasotransmitters and non-canonical organ systems.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Amber N EdinoffDepartment of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-7436-6206
Saveen SallDepartment of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center at Shreveport, Shreveport, LA 71103, USA.
T Dean RobertsCollege of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA.
Henry H TomlinsonDepartment of Anesthesiology, Medical University of South Carolina, Charleston, SC 29425, USA.
Lenise G SoileauSchool of Medicine, Louisiana State University Health Science Center at Shreveport, Shreveport, LA 71103, USA.
Eric D JacksonCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA.
Kevin S MurnaneLouisiana Addiction Research Center, Shreveport, LA 71103, USA.ORCID 0000-0002-8143-0541
Danielle M WengerCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA.
Elyse M CornettLouisiana Addiction Research Center, Shreveport, LA 71103, USA.ORCID 0000-0001-7961-3931
Jaime TomsDepartment of Pharmacology, Toxicology & Neuroscience, Louisiana State University Health Science Center at Shreveport, Shreveport, LA 71103, USA.
Deepak KumbhareDepartment of Neurosurgery, Louisiana State University Health Science Center at Shreveport, Shreveport, LA 71103, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA.ORCID 0000-0002-7224-3322
Alan D KayeLouisiana Addiction Research Center, Shreveport, LA 71103, USA.ORCID 0000-0003-2464-0187
Louisiana State University Health Sciences Center Shreveport · USUniversity of Arizona · USUniversity of the Pacific · USHarvard University · USMedical University of South Carolina · USUniversity of Louisiana at Monroe · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of stimulant use disorder (StUD) involving methamphetamine and cocaine has been a growing healthcare concern in the United States. Cocaine usage is associated with atherosclerosis, systolic and diastolic dysfunction, and arrhythmias. Furthermore, approximately one of every four MIs is cocaine-induced among patients aged 18 to 45. Methamphetamine use has been associated with nerve terminal damage in the dopaminergic system resulting in impaired motor function, cognitive decline, and co-morbid psychiatric disorders. Current treatment options for StUD are extremely limited, and there are currently no FDA-approved pharmacotherapies. Behavioral interventions are considered first-line treatment; however, in a recent meta-analysis comparing behavioral treatment options for cocaine, contingency management programs provided the only significant reduction in use. Current evidence points to the potential of various neuromodulation techniques as the next best modality in treating StUD. The most promising evidence thus far has been transcranial magnetic stimulation which several studies have shown to reduce risk factors associated with relapse. Another more invasive neuromodulation technique being studied is deep-brain stimulation, which has shown promising results in its ability to modulate reward circuits to treat addiction. Results showing the impact of transcranial magnetic stimulation (TMS) in the treatment of StUD are limited by the lack of studies conducted and the limited understanding of the neurological involvement driving addiction-based diseases such as StUD. Future studies should seek to provide data on consumption-reducing effects rather than craving evaluations.

Indexed as

addictioncocainemethamphetamineneuromodulationstimulantstranscranial magnetic stimulation

Identifiers

PMID36976664
PMCPMC10051697
OpenAlexW4322619608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.